Lexaria Bioscience (LEXX)

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

A(z) Lexaria Bioscience Corp. Common Stock (LEXX) részvény mai árfolyama , ami NaN% elmozdulást tükröz a piac nyitása óta. A vállalat piaci kapitalizációja jelenleg 16,42 M $, a napi kereskedési volumen pedig  részvény. A korábbi záró ár volt.

Készen állsz? Kövesd az alábbi lépéseket, vagy olvasd el útmutatónkat a(z) hogyan vásárolj Lexaria Bioscience részvényt a Krakenen, kezdve 10 dollárral.